Arnau Antolí , José Luis Gómez-Vázquez , Angels Sierra-Fortuny , Carla Bermudez-Carre , Mario Framil , Edgar Creus-Bachiller , Julen Viana-Errasti , Paula Rofes , Gemma Rocamora-Blanch , Lara Hidalgo-Peña , Lydia García-Serrano , Raúl Rigo-Bonnin , Lidia Feliubadaló , Jesús del Valle , Laura Calatayud , Francisco Morandeira , Conxi Lázaro , Xavier Solanich
{"title":"Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients","authors":"Arnau Antolí , José Luis Gómez-Vázquez , Angels Sierra-Fortuny , Carla Bermudez-Carre , Mario Framil , Edgar Creus-Bachiller , Julen Viana-Errasti , Paula Rofes , Gemma Rocamora-Blanch , Lara Hidalgo-Peña , Lydia García-Serrano , Raúl Rigo-Bonnin , Lidia Feliubadaló , Jesús del Valle , Laura Calatayud , Francisco Morandeira , Conxi Lázaro , Xavier Solanich","doi":"10.1016/j.clim.2025.110491","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Neutralizing autoantibodies against type I interferons were strongly linked to severe COVID-19 in unvaccinated patients; however, this has yet to be evaluated in vaccinated individuals.</div></div><div><h3>Objective</h3><div>To analyze how these autoantibodies influences disease variability in vaccine breakthrough COVID-19 pneumonia patients.</div></div><div><h3>Methods</h3><div>Clinical and laboratory data; autoantibodies blocking interferon-α2 and –ω; and humoral response to SARS-CoV-2 vaccine were collected from all vaccinated COVID-19 pneumonia patients admitted from April 2021 to December 2022 at Bellvitge University Hospital, Spain.</div></div><div><h3>Results</h3><div>458 patients developed COVID-19 pneumonia despite an appropriate antibody response to SARS-CoV-2 vaccination. Autoantibodies neutralizing interferons were significantly more prevalent in patients with critical pneumonia compared to those with milder forms (8.8 % vs. 3.6 %; <em>p</em> = 0.037). Having these autoantibodies was an independent predictor for critical COVID-19 pneumonia (OR 2.88 [95 %CI 1.18–6.98]).</div></div><div><h3>Conclusion</h3><div>Vaccination considerably reduces the severity of COVID-19; however, patients with type I interferon autoantibodies remain at increased risk of severe disease.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"276 ","pages":"Article 110491"},"PeriodicalIF":4.5000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S152166162500066X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Neutralizing autoantibodies against type I interferons were strongly linked to severe COVID-19 in unvaccinated patients; however, this has yet to be evaluated in vaccinated individuals.
Objective
To analyze how these autoantibodies influences disease variability in vaccine breakthrough COVID-19 pneumonia patients.
Methods
Clinical and laboratory data; autoantibodies blocking interferon-α2 and –ω; and humoral response to SARS-CoV-2 vaccine were collected from all vaccinated COVID-19 pneumonia patients admitted from April 2021 to December 2022 at Bellvitge University Hospital, Spain.
Results
458 patients developed COVID-19 pneumonia despite an appropriate antibody response to SARS-CoV-2 vaccination. Autoantibodies neutralizing interferons were significantly more prevalent in patients with critical pneumonia compared to those with milder forms (8.8 % vs. 3.6 %; p = 0.037). Having these autoantibodies was an independent predictor for critical COVID-19 pneumonia (OR 2.88 [95 %CI 1.18–6.98]).
Conclusion
Vaccination considerably reduces the severity of COVID-19; however, patients with type I interferon autoantibodies remain at increased risk of severe disease.
期刊介绍:
Clinical Immunology publishes original research delving into the molecular and cellular foundations of immunological diseases. Additionally, the journal includes reviews covering timely subjects in basic immunology, along with case reports and letters to the editor.